1263 Characterizing steroid-refractory immunotherapy toxicities and effect of second-line immunosuppression on clinical outcomes

Abstract

BackgroundImmune-related adverse events (irAEs) are major factors limiting optimal application of immune checkpoint inhibitors (ICIs). Up to 30% of irAEs are steroid-refractory, necessitating addition of second-line immunosuppression (2nd-line IS).1 Unfortunately,...